TL033
Based on 1 Customer Validation
TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.11%
- CAS No.: 2356230-22-1
- Formule: C76H103N13O23S2
- Masse moléculaire:1630.83
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Drug-Linker Conjugates for ADC
More
Activité biologique
BT001021 (3 days) shows killing effects (EC50: 13.15 nM) on HCC1806 cells (breast cancer cell line)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCC1806 (Trop-2 positive cell line)
-
Concentration:0-50 nM approximately
-
Incubation Time:3 days
-
Result:Showed cytoxicity with an EC50 value of 13.15 nM.
BT001021 (intravenous injection, 10 mg/kg for a single dose) shows significant tumor tissue targetability and good pharmacokinetic properties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xenograft of a human gastric cancer cell line NCI-N87[1]
-
Dosage:3 mg/kg
-
Administration:Intravenous injection, twice a week for a total of 6 times.
-
Result:Significantly inhibited the tumor growth (114.61%) without significant toxicity.
-
Animal Model:
-
Dosage:10 mg/kg
-
Administration:Intravenous injection, twice a week for a total of 6 times.
-
Result:Effectively inhibited the tumor growth (54.93% for breast cancer, 108.7% for NSCLC).
-
Animal Model:Xenograft of a human gastric cancer cell line NCI-N87 (pharmacokinetic assay)[1]
-
Dosage:10 mg/kg
-
Administration:Intravenous injection for a single dose
-
Result:Pharmacokinetic parameters of BT001021 in tumors and serum.
Tumor Serum Cmax (ng/mL) 7.82 11.7/sub> Tmax (h) 8.0 1.0 T1/2 (h) 93.14 44.35
Chemical Information
-
CAS No. 2356230-22-1
-
Appearance Solid
-
Masse moléculaire 1630.83
-
Formule C76H103N13O23S2
-
Color Light yellow to yellow
-
SMILES
O=C1N2C(C3=NC4=CC=CC=C4C(CCN(C(C)C)S(C)(=O)=O)=C3C2)=CC5=C1COC([C@@]5(CC)OC(OCC6=CC=C(C=C6)NC([C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7C=C(N=N7)CNC(CCCC#CC8=CN=C(S(C)(=O)=O)N=C8)=O)=O)=O)=O)=O)=O
-
Synonyms
Tirumotecan
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TL033 Related Classifications
HY-147340 Related Classifications
Powered by Bioz